Killick Capital

June 25, 2008 – Plasco Energy Group Inc. (“PlascoEnergy”) of Ottawa announced that the Ottawa City Council unanimously agreed to issue a letter of intent to PlascoEnergy to build, own and operate a 400 tonne-per-day waste conversion facility that will process residual householdwaste that would otherwise be sent to landfill.

The City will continue to operate source separation blue box (plastic, metal and glass), black box (paper and paperboard) and yard waste composting programs introduced many years ago, and is currently introducing source separation of organics for anaerobic digestion. The Plasco Conversion Facility will convert substantially all residual household waste to valuable products including synthetic fuel gas for operation of internal combustion engines. Generators driven by the engines and by waste heat from the conversion process and the engines will produce approximately 21 MW of net saleable base-load power for delivery to Hydro Ottawa.

Upon approval, the facility will be funded, built, owned and operated by PlascoEnergy and will be capable of processing 400 tonnes per day (150,000 tonnes per year) of garbage. Garbage will be delivered from local collection trucks to the facility. PlascoEnergy will separate large metal objects prior to feeding the garbage into the conversion system and will send them back to the City for recycling. The City will pay a tipping fee of $60 per tonne of waste processed, escalated to reflect CPI over a 20-year contract. All risks of operation and efficiency of power generation are assumed by PlascoEnergy. The City will receive 25% of annual revenues that exceed an amount mutually agreed to by PlascoEnergy and the City.

The facility will occupy a six-acre site near an existing city owned and operated landfill. The City’s leftover garbage will be converted into synthetic engine fuel, agricultural sulphur, industrial salt and construction aggregate with no emissions to the air, land or water. In addition, the excess moisture in the waste will be recovered through the process as clean water.

The engines will drive electrical generators to produce reliable base-load power. Emissions from the engines will be monitored by continuous emissions monitoring and by periodic source testing. The results of both continuous and source testing will be reported on the ZeroWasteOttawa.com website and will be reviewed by independent experts approved by the Ministry of the Environment (“MOE”). An independent Public Advisory Committee will review and make public comments as it sees fit on the environmental performance of the facility and MOE will assure that the facility continuously meets its environmental requirements under the Ministry’s Certificate of Approval.

The move by City Council comes three years after the Council approved development by
PlascoEnergy of a plant to demonstrate the Plasco Conversion System on a City owned site on the capped Nepean Landfill on Trail Road. The demonstration facility received funding support by Sustainable Development Technology Canada, and from the Ontario Ministry of Research and Innovation. Ottawa provided the demonstration site and has provided garbage for processing at the demonstration plant. The Plasco Trail Road demonstration plant began commissioning in July last year.

“Provided this system meets all the environmental requirements, the City of Ottawa will be supportive,” said Ottawa Mayor Larry O’Brien. “I have always said cities have too much waste and not enough energy and exploring technologies like PlascoEnergy is a positive step forward for our City.”

All necessary permits including Certificates of Approval by the Ontario MOE must be received before commencement of operations. Certificates of Approval will be based on exhaustive operating data from the existing Trail Road Demonstration Facility. The entire process of approvals and construction is expected to take approximately two years.

To see a fact sheet and for more information please visit www.plascoenergygroup.com

About Plasco Energy Group Inc.
Plasco Energy Group Inc. (PlascoEnergy) is an Ottawa-based private Canadian company. PlascoEnergy and its predecessor RCL Plasma, Inc. have operated plasma based R&D and test facilities in Ottawa and Spain for more than a decade. The Plasco Trail Road facility is a full scale semi-commercial demonstration plant using PlascoEnergy proprietary technologies. This project has been supported by a contribution from Sustainable Development Technology Canada, a not-for-profit corporation created by the Government of Canada It has also been supported by a loan from the Ontario Ministry of Research and Innovation under its Innovation Demonstration Fund, and the provision at nominal cost of the site and supply of waste during the demonstration period by the City of Ottawa.

June 19, 2008 – PharmaGap Inc. (TSX-V: GAP) (“PharmaGap” or “the Company”) today announced that it has filed a preliminary short form prospectus in connection with an agreement entered into with Dundee Securities Corporation and Wellington West Capital Inc. (the “Agents”) to raise gross proceeds of approximately $4.5 million (the “Offering”). The Agents, acting as co-leads, have invited Capital Street Group of Vancouver, a Limited Market Dealer, to join as Special Selling Group Member.

The Company is selling equity units consisting of common shares plus common share purchase warrants (the “Units”). The Company has agreed to pay the Agents a selling concession consisting of 10% of proceeds raised, along with broker warrants equal to 10% of the Units issued.

The Company has granted the Agents an option to purchase additional Units, equal to 15% of the Offering, for purposes of covering over-allotments and for market stabilization purposes. The option can be exercised in whole or in part at any time over a period of 30 days following the closing of the Offering, which is expected to occur on or before July 18, 2008. Closing of the Offering is also subject to receipt of all necessary regulatory and TSX-Venture Exchange approvals.

Net proceeds from the Offering will be used primarily to complete studies required to garner regulatory approval in the U.S. and Canada to begin human clinical trials of the Company’s lead drug for cancer treatment, PhG-alpha-1, a novel peptide inhibitor of protein kinase C alpha. In addition, proceeds will also fund continued development of the Company’s drug pipeline, for development of licensing and partnering relationships, and for general corporate and working capital purposes.

The preliminary prospectus is available on SEDAR (www.sedar.com). Copies of the preliminary prospectus are also available from Dundee Securities Corporation and Wellington West Capital Inc.

The Units being offered have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent regulation or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale 0f the securities in any State in which the offer, solicitation or sale would be unlawful.

About PharmaGap Inc.
PharmaGap Inc. (TSX-V: GAP), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel therapeutic compounds for the treatment of cancer. PharmaGap's research platform targets cellular signaling pathways controlled by protein kinase C (PKC) isoforms. PharmaGap's lead drug compound, PhGalpha1, is in preclinical development. The Company's strategy is to out-license drug compounds to larger life sciences companies at the preclinical stage. For more information please visit the Company's website at www.pharmagap.com.

With Over 250,000 Active Users, Celtx Advances Out of Beta

ST. JOHN'S, NL, June 9, 2008 -  Celtx, the world's first fully integrated solution for media pre-production, today announced the free public availability of version 1.0 of their software. The latest version delivers new and improved functionality to media creators around the world combining all pre-production activities and tools in one software suite -- including writing, story development, production breakdown, scheduling and reporting.

Celtx is an innovative, free, integrated pre-production tool used to create, organize & publish film, video, audio, theater, comic books and other media. It also contains an Internet friendly tool that enables collaboration online for script writing, story development and scheduling during the pre- production process helping media creators manage the process despite their location.

It's unique hybrid architecture combines the strengths inherent in a desktop application -- control, stability, power and flexibility, with the strengths inherent with the web -- collaboration, community, publishing, and online back-up. This unique offering combined with availability in 20 languages has made Celtx the world's most widely used pre-production software with over 250,000 active users in 160 countries and 1 million downloads since its launch in 2004.

"Version 1.0 is all about arriving at our goal of making Celtx the world's first full-featured, fully integrated media pre-production software," said Mark Kennedy, CEO of Greyfirst, parent company of Celtx. "We're proud that Celtx is the first software to have everything writers and production teams need to take them all the way from concept to production."

Intended to replace the traditional 'paper, pen & binder' approach to pre- production with a fully digital approach that's more complete, simpler to work with, and easier to share, Celtx has caught on quickly with independent filmmakers, studio professionals, students and media creators the world over.

"As I began my latest project, a friend of mine introduced me to Celtx. Not only has it helped me corral and organize my ideas, but it has also given me the tools to then integrate these thoughts directly into a working script," said independent filmmaker and Celtx user Max Makowski. "The quality of their software is truly a testament to the Celtx team's passion and commitment to providing the film community with an exceptional innovative pre-production tool."

    Celtx 1.0 new features include:

    --  Adapt To - a single click now converts a fully formatted script of one
        type into a fully formatted script of another -- for example a
        Stageplay to a Screenplay -- displaying instantly the multi-media
        potential of your work.
    --  Comic Book - a new editor to write properly formatted Comic
        Books, and a common framework for collaboration between writer and
        artist.
    --  iPhone - now view your Celtx projects from just about anywhere with a
        display optimized for your iPhone.
    --  Catalogs - a new organization and searchable dashboard view of all
        your story's elements and production items.
    --  Sidebar - annotate and break down each scene with notes, media
        (images, audio, and video clips), and production items through an easy
        to manage, thoroughly upgraded new sidebar.
    --  Project Scheduling - has been vastly upgraded to fully integrate with
        the script breakdown and provide a Call Sheet and a host of new
        shooting reports.
    --  Storyboarding - you can now choose from a variety of ways to view and
        manage your images, create a storyboard outline based on your script,
        and add shot descriptions to each image.

    To download Celtx 1.0 free, please visit http://www.celtx.com/
   

About Celtx

Celtx is the world's first fully integrated software solution for media pre-production enabling media collaboration and development across the world. With over 250,000 independent media creators in more than 160 countries working in 20 different languages, Celtx is the global standard for media production for the next generation of media creators to create and develop their own content regardless of location or language. For more information, visit http://www.celtx.com.

About Greyfirst

Celtx is developed by Greyfirst Corp. -- an independent software development company with expertise in Semantic Web and Open Source technologies, committed to developing innovative standards-based softwarem for the next generation of the Internet. For more information, visit
http://www.greyfirst.com.

June 6, 2008 – PharmaGap Inc. (TSX-V: GAP) (“PharmaGap” or “the Company”) today announced the formation of a Clinical Development Group to direct and deliver the Company’s clinical development of its PhG-alpha-1 compound for treatment of cancer. The Clinical Development Group has the mandate to execute the program required to generate the data needed for an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for PhG-alpha-1, for approval for use in humans. These studies, often referred to as IND enabling studies, build upon the compelling animal study data recently announced.

The Company is pleased that Dr. David Barnes, Dr. Douglas Cowart, and Dr. Gary Schwartz have each agreed to join the PharmaGap Clinical Development Group to take PhG-alpha-1 through the process required to gain approval to commence clinical trials in humans. Others will be named to the Group as specific elements of the program require.

Dr. David G. Barnes, a physician and molecular biologist, has worked with industry and government in the clinical development, regulation and safety of biologics since 2001, and has extensive experience with both clinical and preclinical drug development. He is a former clinical evaluator, Biologics and Genetic Therapies Directorate and former head of the Biotechnology Products Surveillance Unit, Marketed Health Products Directorate, Health Canada. Dr. Barnes has served as the Company’s Director of Clinical Development and Regulatory Affairs since 2005, and will have overall responsibility for the program, reporting to Robert. C. McInnis, president of the Company.

Dr. Douglas Cowart, Pharm D. (Medical University of South Carolina), a board certified pharmacologist, has over 25 years experience in clinical trials design and planning, with both FDA and international clinical trials experience in over 50 clinical studies. In his practice, Dr. Cowart has developed a consortium of medical, scientific, and regulatory consultants to facilitate the developmental needs of emerging pharmaceutical, biotechnology, and medical device companies. These same relationships will be brought to bear in pursuing PharmaGap’s clinical development program as required.

Dr. Gary Schwartz, Chief, Melanoma and Sarcoma Service for Sloan-Kettering’s Department of Medicine’s division of Solid Tumor Oncology, has been working with the Company since 2006. Dr. Schwartz is a medical oncologist specializing in the identification and development of new targeted drugs for cancer therapy, specifically aimed at understanding the mechanisms underlying the cell cycle and cell death, and the role that proteins, including protein kinases, play in these mechanisms. He is a Member and Attending Physician at Memorial Sloan-Kettering Cancer Center and Professor of Medicine at Weill Medical College of Cornell University in New York. He is a current member of the American Society of Clinical Oncology’s (ASCO) Cancer Foundation Grants Selection Committee (GSC), a former member of the ASCO Scientific Program and Cancer Education Committees and has served as the American Association of Cancer Researcher’s (AACR) co-Chairperson for the Program Committee on Translational Research in Molecular Biology. Dr. Schwartz is also an Editorial Board Member of the Journal of Clinical Oncology and an Associate Editor of Clinical Cancer Research.

Each of Dr. Barnes, Dr. Cowart, and Dr. Schwartz have developed an extensive network of drug development professionals and contacts within the medical and pharmaceutical industry with specific expertise in all areas of drug development required to take a drug compound into clinical trials. This extended network will be called on to deliver components of the PharmaGap program as required.

Robert C. McInnis, President and C.E.O. of the Company said “We are pleased to have attracted these highly respected physicians to form the core of our clinical development program to take PhG-alpha-1 toward and into clinical trials. I anticipate the naming of other members bringing both general and specific areas of expertise as the program moves forward in the near future. The creation of this development group is significant in that it provides us with a range of experienced professionals working to take PhG-alpha-1 into the clinic that would otherwise not be available to us on a full time staffed basis, at a cost to the Company that provides maximum value to our shareholders.”

The initial work to be undertaken will be directed to standard ADME (Absorption, Distribution, Metabolism, and Excretion) analyses in order to refine the understanding of PhG-alpha-1’s interaction with the human physiology, required for establishment of a therapeutic dose range in humans. This work will be carried out by independent contract research organizations to specifications stipulated by the Company’s clinical development group working in conjunction with Dr. Jenny Phipps, the Company’s Chief Scientific Officer.

The program will also include the optimization of the drug formulation aimed at maximizing the effectiveness, safety, and ease of administration, development of large scale manufacturing processes and process controls, and definitive toxicology studies required to gain approval for use in human clinical trials.

During the course of this clinical development program the Company will continue to develop its pipeline of future drug compounds, and to generate business development opportunities aimed at securing a development partnership, licensing or similar arrangement for PhG-alpha-1 with an established pharmaceutical or biotech company aimed at bringing both additional financial and drug development depth to the program.

About PharmaGap Inc.
PharmaGap Inc. (TSX-V: GAP), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel therapeutic compounds for the treatment of cancer. PharmaGap's research platform targets cellular signaling pathways controlled by protein kinase C (PKC) isoforms. PharmaGap's lead drug compound, PhGalpha1, is in preclinical development. The Company's strategy is to out-license drug compounds to larger life sciences companies at the preclinical stage. For more information please visit the Company's website at www.pharmagap.com.

June 2, 2008 – PharmaGap Inc. (TSX-V: GAP) (“PharmaGap” or “the Company”) released today additional results of animal studies indicating effectiveness of its lead cancer drug, PhG-alpha-1, in treating two types of highly aggressive human colon cancer. These results are consistent with and augment earlier results using breast and colon cancers announced by the Company on April 17, 2008.

The two human cancer cell lines used are both colorectal cancers which are known to be aggressive and difficult to successfully treat.

In these final two of five human cancer models studied, a total of 100 mice in which human colon cancer cells of two different types had previously been implanted subcutaneously and allowed to grow into solid body tumours of a palpable size were then treated with PhG-alpha-1 at three doses (1, 5, and 10 mg/kg body weight), both singly and in combination with chemotherapeutic agents, or received saline solution or the chemotherapeutic agent alone as test controls.

The results indicate an extension of survival and reduction of tumour volume in groups treated with PhG-alpha-1, alone and in combination with chemotherapy.

Robert McInnis, President & CEO commented “We are delighted with this additional compelling evidence of efficacy seen with our lead compound in these most recent results. These cancers are both aggressive and representative of cancers found in real patients. These additional test results add to the body of evidence that PhG-alpha-1 has the potential to be developed into an effective agent against cancer in humans.”

Colon Cancer (early stage type) subcutaneous model
Human colon cancer cells type LS180, known to be highly invasive, were implanted beneath the skin and provided time to develop palpable tumours, following which treatment began.

The group receiving PhG-alpha-1 both singly and in combination treatment exhibited an extension of survival when compared to the group receiving chemotherapy alone. Average days survival following commencement of treatment was 31 for the group receiving chemotherapy alone (with a maximum of 37 days), extended by almost 30% to 40 days in the groups receiving PhG-alpha-1 alone (with a maximum of 56 days), and 32 days in the groups receiving combined treatment (with a maximum of 47 days).

In the group receiving the chemotherapy treatment alone, average tumour volume of 1,000 cubic mm was reached in 26 days, compared to 33 days (26% slower) for the combined treatments at PhG-alpha-1 doses of 5 and 10 mg/kg, and 44 days (69% slower) for groups treated with PhG-alpha-1 alone at each of the 3 doses. Moreover, the average tumour size at time of euthanasia was 3,681 cubic mm for the group receiving the chemotherapy alone, 2,929 cubic mm for all combined treatment groups, and 2,417 cubic mm for the groups receiving PhG-alpha-1 alone. The overall reduction in tumour volume compared to the control group receiving chemotherapy alone was approximately 20% for combined treatments and approximately 34% for groups treated with PhG-alpha-1 alone.

Colon Cancer (later stage type) subcutaneous model
A later stage human colon cancer cell line, known to be highly drug resistant, was implanted beneath the skin and provided time to develop palpable tumours, following which treatment began. In earlier in vitro testing at Memorial Sloan Kettering Cancer Center in New York, PhG-alpha-1 was shown to have a strong effect against this cell line, increasing the efficacy of the chemotherapy agent used by 50%.

This cancer cell line is known to exhibit very slow growth, resulting in a lower number of tumour occurrences in this test cohort. In this current test, observations of mice in which tumours did develop show a positive effect of the combined treatment using PhG-alpha-1 when compared to the mice receiving chemotherapy alone, on both extension of survival and limitation of tumour volume. In ex vivo examination of cells obtained from the tumours, those obtained from the tumours from the combined treatment groups exhibited a very low yield of viable cells compared to the chemotherapy alone group, an additional indicator of effectiveness of the combined PhG-alpha-1 treatment. Overall, these results are consistent with and support those obtained earlier at Memorial Sloan Kettering Cancer Center.

About PharmaGap Inc.
PharmaGap Inc. (TSX-V: GAP), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel therapeutic compounds for the treatment of cancer. PharmaGap's research platform targets cellular signaling pathways controlled by protein kinase C (PKC) isoforms. PharmaGap's lead drug compound, PhGalpha1, is in preclinical development. The Company's strategy is to out-license drug compounds to larger life sciences companies at the preclinical stage. For more information please visit the Company's website at www.pharmagap.com.